The NIHR-supported Novavax COVID-19 vaccine – which was trialled in Exeter and Cornwall – has demonstrated that the vaccine is 89.3% effective at preventing COVID-19.This data was identified from interim analysis of the Phase III study and included effectiveness against the new variants.
The Novavax study is the largest ever double blind, placebo-controlled trial to be undertaken in...
